Showing Results for
- Academic Journals (252)
Search Results
- 252
Academic Journals
- 252
- Search Terms:
- 1From: Molecular Cancer. (Vol. 13) Peer-ReviewedBackground Over 90% of cancer-related deaths in clear cell renal cell carcinoma (RCC) are caused by tumor relapse and metastasis. Thus, there is an urgent need for new molecular markers that can potentiate the efficacy...
- 2From: Molecular Cancer. (Vol. 13) Peer-ReviewedBackground Insulin enhancer binding protein-1 (ISL-1), a LIM-homeodomain transcription factor, is essential for the heart, motor neuron and pancreas development. Recently, ISL-1 has been found in some types of human...
- 3From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedAuthor(s): Takashi Mitamura1,2 , Hidemichi Watari1 , Lei Wang2 , Hiromi Kanno2 , Makiko Kitagawa1 , Mohamed Kamel Hassan1,4 , Taichi Kimura2 , Mishie Tanino2 , Hiroshi Nishihara3 , Shinya Tanaka2,3 and Noriaki Sakuragi1...
- 4From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedAuthor(s): Donatella Del Bufalo1 , Marianna Desideri1 , Teresa De Luca1 , Marta Di Martile1 , Chiara Gabellini1 , Valentina Monica2 , Simone Busso2 , Adriana Eramo3 , Ruggero De Maria4 , Michele Milella5 and Daniela...
- 5From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedAuthor(s): Leah Morenos1,2 , Zac Chatterton1,2 , Jane L Ng1 , Minhee S Halemba1 , Mandy Parkinson-Bates1 , Francoise Mechinaud3 , Ngaire Elwood4 , Richard Saffery1,2 and Nicholas C Wong1,2,5 Background Acute...
- 6From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedAuthor(s): Li-Sheng Chang1,2 , Chih-Hsiang Leng2 , Yi-Chen Yeh2 , Chiao-Chieh Wu2 , Hsin-Wei Chen2,3 , Hai-Mei Huang1 and Shih-Jen Liu2,3 Effective cancer immunotherapies should eradicate cancer cells and block the...
- 7From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedAuthor(s): Lisha Wang1,2 , Sean R Williamson3 , Mingsheng Wang2 , Darrell D Davidson2 , Shaobo Zhang2 , Lee Ann Baldridge2 , Xiang Du1 and Liang Cheng2 Renal cell carcinoma (RCC) comprises a heterogeneous group of...
- 8From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedAuthor(s): Mi Hou1 , Emma Eriksson1 , Konstantin Svechnikov1 , Kirsi Jahnukainen1,2 , Olle Söder1 , Andreas Meinhardt3 and Lars Sävendahl1 Background Despite highly improved anti-cancer strategies and increasing...
- 9From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedBackground Gallbladder carcinoma (GBC) is highly lethal, and effective treatment will require synergistic anti-tumor management. The study is aimed at investigating the oncolytic value of myxoma virus (MYXV)...
- 10From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedBackground The metastasis of hematogenous cancer cells is associated with abnormal glycosylation such as sialyl lewis antigens. Although the hepatitis B virus X protein (HBx) plays important role in liver disease,...
- 11From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedEarly in cancer development, tumour cells express vascular endothelial growth factor (VEGF), a secreted molecule that is important in all stages of angiogenesis, an essential process that provides nutrients and oxygen...
- 12From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedBackground The permanent down-regulated expression of T-cell intracellular antigen (TIA) proteins in HeLa cells improves cytoskeleton-mediated functions such as cell proliferation and tumor growth. Methods...
- 13From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedBackground Acylglycerol kinase (AGK) is reported to be overexpressed in multiple cancers. The clinical significance and biological role of AGK in breast cancer, however, remain to be established. Methods AGK...
- 14From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedIntroduction ERBB3, one of the four members of the ErbB family of receptor tyrosine kinases, plays an important role in breast cancer etiology and progression. In the present study, we aimed to identify novel miRNAs...
- 15From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedBackground About 20% of patients diagnosed with endometrial cancer (EC) are considered high-risk with unfavorable prognosis. In the framework of the European Network for Individualized Treatment in EC (ENITEC), we...
- 16From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedBackground Estrogen receptor (ER) [beta] acts as a tumor suppressor in malignant mesotheliomas. Methods Here we explored the anti-proliferative and anti-tumorigenic efficacy of the selective ER[beta] agonist,...
- 17From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedBackground Tumor cell subpopulations can either compete with each other for nutrients and physical space within the tumor niche, or co-operate for enhanced survival, or replicative or metastatic capacities. Recently,...
- 18From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedBackground Increased infiltration of CD8.sup.+T cells into tumors has a positive impact on survival. Our previous study showed that doxorubicin (Dox) plus interleukin-12 (IL-12) boosted the accumulation of CD8.sup.+T...
- 19From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedBackground Cancer-testis (CT) antigen genes might promote the progression of multiple myeloma (MM). CT antigens may act as diagnostic and prognostic markers in MM, but their expression levels and clinical...
- 20From: Molecular Cancer. (Vol. 13, Issue 1) Peer-ReviewedAuthor(s): Seung Ho Choi1,2 , Heekyoung Yang2,3 , Seung Ho Lee1 , Joo-Hyun Ki2 , Do-Hyun Nam1,3,4 and Hae Yong Yoo1,2 Background Brain metastases occur in 20 to 40% of all patients with cancer [1]. The problem is...